Today's Debate: Is Pharma pity party warranted?

The industry admits to having attracted $47 billion in venture capital over the last year, and biotech firms now have $500 billion in capitalization. Yet they're complaining. Should they be?

PHRMA logoBig pharma went to Weston, Florida, a town pulled out from what was the Everglades, and held a pity party this week.

Technically the event was the 10th BioFlorida conference, a celebration of networking for the state's biotech industry.

But the report of Stephen Pounds in The Palm Beach Post sure reads like a pity party:

  • 46 states enacted "anti-industry" legislation in the last year, complained Phrma lobbyist Christopher Badgley.
  • Drug salesmen at Miami's public hospital have to register as lobbyists.
  • Washington is pressing the industry to allow "generic" versions of early biologic drugs.
  • New Jersey is investigating payments made to doctors testing new drugs.

The industry faces drug-price controls, limits on patient access to new treatments, drug-safety concerns, mounting clinical-trial disclosure rules and changes to intellectual-property laws, Badgley concluded.

It's not all bad. The industry admits to having attracted $47 billion in venture capital over the last year, and biotech firms now have $500 billion in capitalization. Yet they're complaining.

Should they be?

Newsletters

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
See All
See All